Fundraising Fox
/Companies
Sign in

Retension Pharmaceuticals

Mclean, US · Founded 2023 · Delaware corporation · 13 employees on LinkedIn

Find your way into Retension Pharmaceuticals

Sign up to see every warm intro you have to Retension Pharmaceuticals

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Retension Pharmaceuticals team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Retension Pharmaceuticals is a clinical-stage biopharmaceutical company developing treatments for hypertension and cardiovascular disease. The company's lead compound, RTN-001, is a tissue-targeted PDE5 inhibitor designed to treat resistant hypertension through a differentiated mechanism targeting the central pulmonary vasculature.

BiotechHealthtechMedical Devices

Founders & leadership

EK
Eric KellerCEO and Co-Founder

Board

MB
Michael BerendtBoard director
DO
Donald OldsBoard director

Funding

SEC filings, press & company announcements

$22.4M disclosed across 2 of 3 rounds · 2023–2025

▶$12.3MraisedMay 2025 · 98 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Eric KellerExecutive Officer, Director
  • Michael BerendtDirector
  • Donald OldsDirector
Offering amount
$20M
Amount sold
$12.3M
Sales commissions
$701.4K
Placement agents
Collage Venture Partners, LLC, Stonehaven, LLC
First sale
Apr 2025
Incorporated
Corporation, Delaware, 2023
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$10.1MraisedMay 2024 · 132 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Donald OldsDirector
  • Michael BerendtDirector
  • Eric KellerExecutive Officer, Director
Offering amount
$11M
Amount sold
$10.1M
Sales commissions
$727.5K
Placement agents
Stonehaven, LLC, Collage Venture Partners, LLC
First sale
Nov 2023
Incorporated
Corporation, Delaware, 2023
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Founder mafia

2 people who came through Retension Pharmaceuticals went on to found or lead other companies.

Ricky BarrettDirector of BD & IRFounded Guardian BioShoshana ShendelmanPresidentFounded Applied Therapeutics

Related companies · 4

Redica SystemsRedica offers an AI-enriched intelligence platform that unifies global regulatory, inspection, site, and post-market data to help companies manage risk and protect product quality. It serves quality, regulatory, and supply chain teams across industries including pharmaceutical, medtech, cosmetics, supplements, food, and financial services.
Reven PharmaceuticalsReven is a biotech company developing RJX technology to address treatment needs for patients with limited therapeutic options. The company has conducted over a decade of research, including FDA-approved clinical studies and is currently investigating the technology's applications across multiple treatment modalities.
AdarepharmasolutionsAdare Pharma Solutions is a CDMO (contract development and manufacturing organization) and pharma services provider serving the biopharma industry with manufacturing, research and development, and patient support capabilities.
FoxbusinessFOX Business Network is a financial news channel that delivers real-time business and market information across multiple platforms. The network serves investors and business audiences interested in news affecting both retail and institutional markets.

Companies working in the same space as Retension Pharmaceuticals.

In the news

Retension Pharmaceuticals Announces Completion of Series B Financing to Advance Phase 2b Trial for Uncontrolled and Resistant Hypertension and Issuance of a New U.S. Patent Covering its Lead Candidate, RTN-001 - BioSpacebiospace.com · Aug 2025

Frequently asked questions

What does Retension Pharmaceuticals do?
Retension Pharmaceuticals is a clinical-stage biopharmaceutical company developing treatments for hypertension and cardiovascular disease. The company's lead compound, RTN-001, is a tissue-targeted PDE5 inhibitor designed to treat resistant hypertension through a differentiated mechanism targeting the central pulmonary vasculature.
How much funding has Retension Pharmaceuticals raised?
Retension Pharmaceuticals has disclosed $22.4M raised across 2 of its 3 known rounds.
Where is Retension Pharmaceuticals headquartered?
Retension Pharmaceuticals is headquartered in Mclean, US.